Researchers assessed the ability of environmental screening as a proxy for patient colonization to reduce transmission of MRSA and VRE in nursing facilities.
In an attempt to determine if the presence of S aureus could be used as a marker for more severe disease, investigators assessed the relationship between S aureus-positive bronchiectasis infection and pulmonary function, frequency of exacerbations, and hospital admissions.
Further studies are warranted to assess the efficacy and safety of fosfomycin plus imipenem against methicillin-resistant Staphylococcus aureus complicated infections.
MRSA nares screening can be a stewardship tool to streamline empiric antibiotic therapy among those not nares colonized with MRSA.
Theravance Biopharma announced positive results from 3 studies on Vibativ (telavancin), a lipoglycopeptide antibiotic.
Researchers found that, over 8 years, MRSA health care-associated infection rates significantly declined.
The use of prophages can reduce invasiveness in S aureus infections of diabetic foot ulcers that limit intracellular growth.
Community-acquired Staphylococcus aureus bacteremia risk rose along with the dosage.
During study period, decrease noted in S. aureus susceptibility to clindamycin.
Risk up seven-fold among patients with type 1 diabetes, almost three-fold for those with type 2.
Higher clinical cure rate compared with placebo in setting in which MRSA was prevalent.
Daily review of prescriptions linked to reduction in time to administer effective antimicrobials.
Actavis announced results for its Phase 3 DUR001-303 study of single dose Dalvance for the treatment of acute bacterial skin and skin structure infections.
Researchers were shocked to discover that a medieval remedy for eye infections may be effective against up to 90 percent of methicillin-resistant Staphylococcus aureus (MRSA) infections.
A new software program called OSPREY has shown promise in predicting drug resistant mutations in response to early-stage leads.